2,4-diaminopyrimidine compounds useful as immunosuppressants

Details 2,4-diaminopyrimidine compounds useful as immunosuppressants 2,4-diaminopyrimidine compounds useful as immunosuppressants

2006-09-05

2006-09-05

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S212070, C514S221000, C514S249000, C514S252020, C514S265100, C514S275000, C540S552000, C540S567000, C540S593000, C544S238000, C544S280000, C544S323000, C544S324000

Reexamination Certificate

active

07101869

ABSTRACT:
Novel compounds according to the formulaand pharmaceutically acceptable salts, solvates, or hydrates thereof; whereineach occurrence of A is independently selected from CH or N;X is selected from the group consisting of —CH2—, —O—, —NH—, (C1-C6)alkylamino-, (C1-C6)alkylaminocarbonylamino-, (C1-C6)alkylcarbonylamino-, (C1-C6)alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C1-C6)alkyl-C(O)—, —S(O)y— where y is 0, 1 or 2, and;n in —(CH2)n— is 1, 2 or 3; andR1, R2, and R3are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.

REFERENCES:
patent: 5304555 (1994-04-01), Awaya et al.
patent: 5358945 (1994-10-01), Mizuchi et al.
patent: 0489925 (1992-06-01), None
patent: 0837063 (1998-04-01), None
patent: WO9200970 (1992-01-01), None
patent: WO9719065 (1997-05-01), None
patent: WO9740019 (1997-10-01), None
patent: WO9744326 (1997-11-01), None
patent: WO9811095 (1998-03-01), None
patent: WO9818782 (1998-05-01), None
patent: WO9828281 (1998-07-01), None
patent: WO9841525 (1998-09-01), None
patent: WO9854156 (1998-12-01), None
patent: WO9854157 (1998-12-01), None
patent: WO9909845 (1999-03-01), None
patent: WO9910341 (1999-03-01), None
patent: WO9924035 (1999-05-01), None
patent: WO0024744 (2000-05-01), None
patent: WO0053595 (2000-09-01), None
Johnson et al., Cutaneous T-cell lymphoma, http://www.healthatoz.com/healthatoz/Atoz/ency/cutaneous_t-cell_lymphoma.html, Dec. 2002.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Rutella et al., PubMed Abstract (Exp Hematol 29(4):401-15), Apr. 2001.
Irani et al., PubMed Abstract (J Immunol 158(5):2318-26), Mar. 1997.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15) May 1999.
Bremer et al., Therapy of Crohn's Disease in Childhood, Exp Opin Pharmacother, 3(7):809-825, 2002.
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21stCentury, Eur. J. Surg. Suppl. 582:90-98, 1998.
Singh et al., Immune Therapy in Inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, 1558-1569, 2001.
Wachlin et al., IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction, Journal of Autoimmunity, 20:303-312, 2003.
Elgert, Autoimmunity, Immunology: Understanding the Immune System, pp. 315-330, 1996.
Beers et al., Crohn's Disease and Ulcerative Colitis, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (Online), 1999.
Hanke, J. H., et al.,Role of tyrosine kinases in lymphocyte activation: Targets for drug intervention, Inflamm. Res.,vol. 44, pp. 357-371, (1995).
Molina, T. J., et al.,Profound block in thymocyte development in mice lacking p56lck, Nature,vol. 357, May 14, 1992, pp. 161-164.
June, Carl H., et al.,Increases in tyrosine phosphorylation are detectable before phospholipase c activation after T cell receptor stimulation, Journal of Immunology,vol. 144, pp. 1591-1599, No. 5, Mar. 1, 1990.
Straus, David B., et al.,Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor, Cell,vol. 70, pp. 585-593, Aug. 21, 1992.
June, Carl H., et al.,Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction, Proc. Natl. Acad. Sci. USA,vol. 87, pp. 7722-7726, Oct. 1990.
English language equivalent of WO 92/00970, 1992.

Affiliated with

Also associated with

Rating

2,4-diaminopyrimidine compounds useful as immunosuppressants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,4-diaminopyrimidine compounds useful as immunosuppressants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-diaminopyrimidine compounds useful as immunosuppressants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3576733